Specialty Pharmacy

Top news of the day from across the health care landscape.

Discrepancies found when comparing real-world findings to clinical trial findings.

Preliminary trial finds moderate-intensity exercise does not increase adverse events in this patient population.

Researchers sought to change the volume of fatty deposits in a coronary artery that was at least 30% blocked.

Study compares common treatment options to prevent recurrent venous thromboembolism.

Top news of the week in oncology and cancer drug development.

Complications associated with left main bifurcation can impact stent choice.

A multi-faceted screening approach could prevent sudden cardiac deaths in young athletes.

Including warning labels may improve healthy eating habits.

Treatments have only increased 10% in hospitals nationwide over the past decade.

A self-expanding transcatheter aortic valve replacement (TAVR) procedure was just as effective as surgery in intermediate risk patients.

The Patient Navigator Program reduced readmission for heart attack or heart failure patients by 81.3%.

The PCSK9 inhibitor dramatically reduces high cholesterol and cuts the risk of heart attack and stroke.

The Blueprint for Transparency at the FDA provides 18 recommendations for the release of regulatory information and data.

Study is the first to examine the function of SP140 protein in inflammatory diseases.

Insulin could become a new therapeutic option for HIV-associated neurocognitive disorders.

Autumn Bagwell, PharmD, BCPS, clinical pharmacist at Vanderbilt Specialty Pharmacy, discusses methods pharmacists can employ to maintain adherence.

Top news of the day from across the health care landscape.

A combination drug regimen may be the answer to treating acute myeloid leukemia.

Evolocumab offers a 25% reduction in cardiovascular (CV) death, heart attack, or stroke after the first year.

Finalists and winners in inaugural awards program to be honored at Asembia 2017

Small case report found an association between the Zika virus and cardiovascular complications.

FOURIER trial meets its primary composite endpoint reducing cardiovascular risk factors.

Mylan gains global licenses for its biosimilar to trastuzumab (Herceptin).

Senescent cells communication via integrin beta 3 expression.

Daniel P. Kus, BS Pharm, RPh, vice president, Pharmacy Advantage, discusses key quality measures that define successful specialty pharmacies.

ATR mutations increase skin cancer tumor growth by modulating the tumor microenvironment.

Some high-risk patients have better than expected outcomes due to frequent follow-up by physicians.